Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The bright side of dark matter: lncRNAs in cancer
Joseph R. Evans, … , Felix Y. Feng, Arul M. Chinnaiyan
Joseph R. Evans, … , Felix Y. Feng, Arul M. Chinnaiyan
Published August 1, 2016
Citation Information: J Clin Invest. 2016;126(8):2775-2782. https://doi.org/10.1172/JCI84421.
View: Text | PDF
Review

The bright side of dark matter: lncRNAs in cancer

  • Text
  • PDF
Abstract

The traditional view of genome organization has been upended in the last decade with the discovery of vast amounts of non–protein-coding transcription. After initial concerns that this “dark matter” of the genome was transcriptional noise, it is apparent that a subset of these noncoding RNAs are functional. Long noncoding RNA (lncRNA) genes resemble protein-coding genes in several key aspects, and they have myriad molecular functions across many cellular pathways and processes, including oncogenic signaling. The number of lncRNA genes has recently been greatly expanded by our group to triple the number of protein-coding genes; therefore, lncRNAs are likely to play a role in many biological processes. Based on their large number and expression specificity in a variety of cancers, lncRNAs are likely to serve as the basis for many clinical applications in oncology.

Authors

Joseph R. Evans, Felix Y. Feng, Arul M. Chinnaiyan

×

Figure 1

Scale of lncRNA genes.

Options: View larger image (or click on image) Download as PowerPoint
Scale of lncRNA genes.
The identification of lncRNA genes has progressed...
The identification of lncRNA genes has progressed rapidly since their recognition. Early efforts identified several thousand lncRNA genes at a time, and there were initial indications that lncRNAs exhibited greater expression restriction than protein-coding genes. Through our large-scale MiTranscriptome bioinformatics effort, we greatly expanded the number of lncRNAs to nearly 60,000, while the number of protein-coding genes remained approximately 21,000. Additionally, our pipeline demonstrated that nearly 8,000 lncRNA genes were highly cancer and/or lineage specific.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts